Method of inhibiting and immune response to a recombinant vector
US6525029B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 29, 1998 |
| Grant date | Feb 25, 2003 |
| Priority date | — |
| Expiry date | Oct 29, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides, among other things, a method of inhibiting an immune response to a recombinant vector, such as a viral vector, specifically an adenoviral vector. The method comprises contacting a cell with (i) a recombinant vector, preferably a viral vector, most preferably an adenoviral vector, comprising a transgene and (ii) a means of inhibiting an immune response to the recombinant vector selected from the group consisting of a TNF receptor fusion protein, a Fas receptor fusion protein, an IFN receptor fusion protein, a gene encoding a TNF receptor fusion protein, a gene encoding a Fas receptor fusion protein, and a gene encoding an IFN receptor fusion protein, whereupon an immune response to the recombinant vector is inhibited. In this regard, the present invention also provides a recombinant vector and a composition for use in the method.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.